Tempus to Acquire Personalis for $1.5B in Stock, Adding MRD to AI Oncology Platform
PSNL has more than doubled off its 52-week low of $3.84 on elevated volume (1.9× avg).
Summary
Tempus AI will acquire Personalis for $1.5 billion in stock, integrating its MRD test into Tempus' AI-enabled precision oncology platform. Personalis shareholders receive $16.25 per share, a 6% premium, with preliminary Q2 results showing strong clinical volume growth.
Key Events · M&A and Partnerships · PSNL
-
Acquisition by Tempus AI
Tempus AI will acquire Personalis for $1.5 billion in an all-stock transaction at $16.25 per share, a 6% premium to the prior close and 28% premium to the unaffected 30-day VWAP.
-
Preliminary Q2 2026 Results
Personalis reported preliminary Q2 revenue of $22.4 million and 10,384 clinical tests, a 33% increase quarter-over-quarter, indicating strong commercial momentum.
-
Strategic Rationale
The deal combines Personalis' ultrasensitive MRD technology with Tempus' AI platform and commercial infrastructure, targeting the $20 billion MRD market and expanding across the cancer care continuum.
-
Transaction Structure
Consideration is 100% Tempus stock with a floating exchange ratio capped at 0.3356; Tempus may elect to pay up to 50% in cash. Closing is expected in late 2026 or early 2027, subject to approvals.
Analysis · PSNL · Industrial Applications And Services
In a move that reshapes the oncology diagnostics landscape, Tempus AI is acquiring Personalis for $1.5 billion in an all-stock deal at $16.25 per share, a 6% premium to the prior close. The combination brings together Personalis' industry-leading MRD technology with Tempus' commercial scale and AI platform, targeting a $20 billion market. Accelerating commercial traction is evident in Personalis' preliminary Q2 revenue of $22.4 million and a 33% sequential jump in clinical test volumes. The deal is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals.
At the time of this filing, PSNL was trading at $14.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.84 to $16.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.